Aquatic Capital Management LLC Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Aquatic Capital Management LLC raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 201.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 235,414 shares of the biopharmaceutical company's stock after acquiring an additional 157,214 shares during the quarter. Aquatic Capital Management LLC owned approximately 0.08% of Amicus Therapeutics worth $2,218,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. lifted its stake in Amicus Therapeutics by 4.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company's stock worth $289,000 after acquiring an additional 1,280 shares during the last quarter. Xponance Inc. lifted its stake in Amicus Therapeutics by 11.9% in the fourth quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company's stock worth $200,000 after acquiring an additional 2,249 shares during the last quarter. Covestor Ltd lifted its stake in Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after acquiring an additional 2,312 shares during the last quarter. KBC Group NV lifted its stake in Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after acquiring an additional 3,120 shares during the last quarter. Finally, Swiss National Bank lifted its stake in Amicus Therapeutics by 0.7% in the fourth quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company's stock worth $4,121,000 after acquiring an additional 3,200 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Wells Fargo & Company lowered their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Amicus Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $16.75.

Amicus Therapeutics Price Performance

Shares of FOLD opened at $7.39 on Tuesday. Amicus Therapeutics, Inc. has a fifty-two week low of $6.20 and a fifty-two week high of $12.65. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -41.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.79. The firm has a 50-day simple moving average of $8.11 and a 200-day simple moving average of $9.37. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.